Skip to content

Tesaro worth $240/share in takeout: SunTrust

June 2, 2017

SunTrust’s Peter Lawson says TESARO (TSRO +1%), once again abuzz with takeout chatter, should fetch $240 (59% upside) a share. A key upcoming event is the release of late-stage data (ARIEL 3 study) on Clovis Oncology’s Rubraca (rucaparib), a competitive PARP inhibitor to ZEJULA (niraparib), at the end of the month. The results should “clarify the competitive landscape” for potential acquirers.

According to a recent report by the WSJ, the level of interest in a takeover has been a bit soft after the company reached out to prospective buyers about a possible transaction.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: